Clinical Trials
50 trialsIFM2012-03
University Hospital, Lille
HO95
Stichting Hemato-Oncologie voor Volwassenen Nederland
Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplantation
National Institutes of Health Clinical Center (CC)
A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma
Janssen Research & Development, LLC
A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens
Janssen Research & Development, LLC
A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma
Janssen Research & Development, LLC
Lenalidomide and Dexamethasone Versus Melphalan Prednisone and Lenalidomide Versus Cyclophosphamide, Prednisone and Lenalidomide in Elderly Multiple Myeloma Patients
Fondazione EMN Italy Onlus
MPRvsMEL200
Fondazione EMN Italy Onlus
A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)
Janssen Research & Development, LLC
MUKtwelve
University of Leeds
MVP
Duke University
Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients
Oncotherapeutics
Thalidomide and Prednisone After Autologous Stem Cell Transplantation Multiple Myeloma
Canadian Cancer Trials Group
Velcade, Melphalan, Prednisone And Thalidomide Versus Velcade, Melphalan, Prednisone in Multiple Myeloma Patients
Fondazione EMN Italy Onlus
RP_MPR
Fondazione EMN Italy Onlus
PCP
Fondazione EMN Italy Onlus
Study of Single Agent Lenalidomide in Older Adults With Newly Diagnosed Multiple Myeloma
H. Lee Moffitt Cancer Center and Research Institute
Modified Stem Cell Transplant Procedure to Treat Patients With Blood and Immune System Cancers
National Institutes of Health Clinical Center (CC)
BPV
University Hospital Heidelberg
Combination Chemotherapy in Treating Patients With Multiple Myeloma
Canadian Cancer Trials Group
Thalidomide and Prednisone Following Peripheral Stem Cell Transplantation in Treating Patients With Multiple Myeloma
Canadian Cancer Trials Group
FIRST
Celgene
Melphalan, Prednisone, and Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
Mayo Clinic
CLARION
Amgen
Study of Oral Ixazomib in Combination With Melphalan and Prednisone in Participants With Newly Diagnosed Multiple Myeloma
Takeda
Chemotherapy, Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma
National Institutes of Health Clinical Center (CC)
A Study of Oprozomib, Melphalan, and Prednisone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma
Amgen
Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone
PETHEMA Foundation
S0204 Thalidomide, Chemotherapy, and Peripheral Stem Cell Transplant in Treating Patients With Multiple Myeloma
SWOG Cancer Research Network
Phase II Study of Revlimid®, Oral Cyclophosphamide and Prednisone for Patients With Newly Diagnosed Multiple Myeloma
Indiana University
Bendamustine, Bortezomib (Velcade ®) and Prednisone (BVP) in Patients Newly Diagnosed Multiple Myeloma
PETHEMA Foundation
MPTD
University of Turin, Italy
RMPT
Fondazione EMN Italy Onlus
REPEAT
UMC Utrecht
Observational Study to Evaluate the Efficacy and Safety of Bortezomib, Melphalan, Prednisone (VMP) in Participants With Multiple Myeloma
Janssen Korea, Ltd., Korea
SWOG-9321 Melphalan, TBI, and Transplant vs Combo Chemo in Untreated Myeloma
SWOG Cancer Research Network
A Study to Compare CNTO 328 (Anti-IL-6 Monoclonal Antibody) and VELCADE-Melphalan-Prednisone (VMP) With VMP Alone in Previously Untreated Multiple Myeloma Patients
Janssen Research & Development, LLC
Celgene High Risk Multiple Myeloma (MM) Revlimid Induction and Maintenance Therapy
Duke University
UPFRONT
Millennium Pharmaceuticals, Inc.
Combination Chemotherapy Following GM-CSF in Treating Patients With Multiple Myeloma
National Cancer Institute (NCI)
Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer
University of California, San Francisco
Rituximab in Treating Patients With Multiple Myeloma
National Cancer Institute (NCI)
Combination Chemotherapy With or Without High Dose Cyclophosphamide and Recombinant Interferon Alfa-2b in Treating Patients With Previously Untreated Stage I-III Multiple Myeloma
National Cancer Institute (NCI)
SWOG-9239 Reduction of Immunosuppression Plus Interferon Alfa and Combination Chemotherapy in Treating Patients With Malignant Tumors That Develop After Organ Transplant
SWOG Cancer Research Network
Bone Marrow and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
Northwestern University
T-Cell-Depleted Allogeneic Stem Cell Transplantation After Immunoablative Induction Chemotherapy and Reduced-Intensity Transplantation Conditioning in Treating Patients With Hematologic Malignancies
National Institutes of Health Clinical Center (CC)
Velcade-Melphalan-Prednisone in Older Untreated Multiple Myeloma Patients.
PETHEMA Foundation
A Randomized Study With Oral Melphalan + Prednisone (MP) Versus Melphalan, + Prednisone + Thalidomide (MPT) for Newly Diagnosesd Elderly Patients With Multiple Myeloma
Gruppo Italiano Studio Linfomi
Methotrexate and Glucocorticoids in Treating Patients With Newly Diagnosed Acute Graft-Versus-Host Disease After Donor Stem Cell Transplant
Fred Hutchinson Cancer Center
Alemtuzumab and Glucocorticoids in Treating Newly Diagnosed Acute Graft-Versus-Host Disease in Patients Who Have Undergone a Donor Stem Cell Transplant
Fred Hutchinson Cancer Center